Rapamycin and mTORC1 Inhibition in the Mouse: Skin Cancer Prevention
Year: 2011
Type: article
Abstract: Therapeutic and preventive effects of rapamycin include reduced risk of nonmelanoma skin cancer (NMSC). In this issue of the journal (beginning on page 1011), Checkley and colleagues report that rapamycin inhibits mTOR complex 1 in murine epidermis, thereby inhibiting tumor promotion mediated by tetradecanoyl phorbol-13 acetate in association with a strong anti-inflammatory effect. Rapamycin is an immunosuppressive drug for preventing graft rejection in organ transplant recipients and reduces the risk of NMSC and Kaposi's sarcoma in this population, albeit by mechanisms distinct from immunosuppression. Important future directions include identifying molecular predictors of rapamycin/rapalog sensitivity or resistance (potentially, for example, PI3K pathway alterations and KRAS mutations) and combined non-rapalog, mTOR-targeting approaches, all of which should increase efficacy and minimize toxicity.
Source: Cancer Prevention Research
Authors: Mohammad Athar, Levy Kopelovich
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Awards: In vitro and In Vivo screening of chemopreventive agents, Role of p53 and ptc tumor suppressive pathways in BCCs development and prevention, Developing a murine model for arsenic-induced skin neoplasm, Inhibiting Multiple Molecular Targets for Preventing Non-Melanoma Skin Cancer, G4458557190, UAB Skin Diseases Research Center, G5773227921, In vitro and In Vivo screening of chempreventive agents
OpenAlex ID: W2153582124